Back to top
more

Doximity (DOCS)

(Delayed Data from NYSE)

$75.12 USD

75.12
1,364,908

+0.72 (0.97%)

Updated Sep 29, 2025 04:00 PM ET

After-Market: $75.14 +0.02 (0.03%) 6:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (63 out of 245)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Do Options Traders Know Something About Doximity Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to DOCS stock based on the movements in the options market lately.

Indrajit Bandyopadhyay headshot

OptimizeRx Bets on AI and Workflow Integration: Will This Pay Off?

by Indrajit Bandyopadhyay

OPRX doubles down on AI and subscriptions, but margin mix and retention risks loom over its platform transformation.

Indrajit Bandyopadhyay headshot

OPRX Shares Rise 69.3% in 3 Months: Time to Bet on the Stock?

by Indrajit Bandyopadhyay

OPRX surged 69.3% in three months as rising contracted revenue and subscription gains boost confidence and guidance.

Zacks Equity Research

Doximity (DOCS) Laps the Stock Market: Here's Why

by Zacks Equity Research

Doximity (DOCS) concluded the recent trading session at $61.09, signifying a +1.13% move from its prior day's close.

Indrajit Bandyopadhyay headshot

Does DOCS' Shift Toward Enterprise Offerings Signal a Long-Term Pivot?

by Indrajit Bandyopadhyay

DOCS sharpens its enterprise focus with AI and workflow tools, signaling a deeper pivot beyond pharma marketing roots.

Indrajit Bandyopadhyay headshot

Will AI Tools Like DocsGPT Drive the Next Leg of Growth for DOCS?

by Indrajit Bandyopadhyay

DOCS is leaning on AI tools like Doximity GPT to fuel growth after a strong FY25, but monetization remains early-stage.

Indrajit Bandyopadhyay headshot

DOCS vs. IRTC: Who Will Win High-Stakes AI Showdown in Digital Health?

by Indrajit Bandyopadhyay

DOCS and IRTC are redefining digital health with AI, but only one is winning big with investors in 2025's market surge.

Zacks Equity Research

EXEL or ARGX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

EXEL vs. ARGX: Which Stock Is the Better Value Option?

Zacks Equity Research

AGM vs. ZG: Which Stock Is the Better Value Option?

by Zacks Equity Research

AGM vs. ZG: Which Stock Is the Better Value Option?

Zacks Equity Research

VOYA or SLF: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

VOYA vs. SLF: Which Stock Is the Better Value Option?

Zacks Equity Research

BBD vs. HDB: Which Stock Is the Better Value Option?

by Zacks Equity Research

BBD vs. HDB: Which Stock Is the Better Value Option?

Zacks Equity Research

GEF vs. PKG: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

GEF vs. PKG: Which Stock Is the Better Value Option?

Zacks Equity Research

APELY vs. OLED: Which Stock Is the Better Value Option?

by Zacks Equity Research

APELY vs. OLED: Which Stock Is the Better Value Option?

Zacks Equity Research

OGN or DOCS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

OGN vs. DOCS: Which Stock Is the Better Value Option?

Debanjana Dey headshot

HIMS' Subscriptions Power Personalized Care & Recurring Revenue Growth

by Debanjana Dey

Hims & Hers' 38.4% subscriber growth and $576.4 million online revenues highlight the power of its personalized subscription model.

Debanjana Dey headshot

DOCS Boosts Client Retention via Workflow Integration and AI Tools

by Debanjana Dey

Doximity strengthens client loyalty by embedding AI tools and clinical workflows into its platform for medical professionals.

Indrajit Bandyopadhyay headshot

Doximity Declines 4.4% in a Month: How to Play the Stock Now?

by Indrajit Bandyopadhyay

DOCS slips 4.4% in a month despite strong Q4 results, margin gains and raised guidance -- is there a buying opportunity?

Indrajit Bandyopadhyay headshot

Doximity Rides on Telehealth Demand: Will This Drive Sales Further?

by Indrajit Bandyopadhyay

DOCS posts strong Q4 revenue growth and record user engagement as demand for telehealth and AI tools hits new highs.

Zacks Equity Research

Doximity Stock Plunges Despite Q4 Earnings & Sales Beat, Margins Up

by Zacks Equity Research

DOCS reports robust growth in unique active users and sales of workflow tools, driving the top and bottom lines. First-quarter fiscal 2026 sales outlook below estimates.

Zacks Equity Research

Doximity (DOCS) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Doximity (DOCS) delivered earnings and revenue surprises of 40.74% and 3.39%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Biodesix, Inc. (BDSX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Biodesix (BDSX) delivered earnings and revenue surprises of 0% and 7.19%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Doximity Q4 Earnings Likely to Reflect Strong Product Momentum

by Zacks Equity Research

Doximity's Q4 performance likely witnessed strong product-driven gains from new modules and integrated programs, though early revenue pull-forward might have tempered sequential growth.

Zacks Equity Research

Progyny (PGNY) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Progyny (PGNY) delivered earnings and revenue surprises of 6.67% and 6.60%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Doximity (DOCS) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Doximity (DOCS) concluded the recent trading session at $59.39, signifying a +0.1% move from its prior day's close.

Zacks Equity Research

SOLV vs. DOCS: Which Stock Is the Better Value Option?

by Zacks Equity Research

SOLV vs. DOCS: Which Stock Is the Better Value Option?